196 related articles for article (PubMed ID: 38731471)
1. CBD in the Treatment of Epilepsy.
Borowicz-Reutt K; Czernia J; Krawczyk M
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731471
[TBL] [Abstract][Full Text] [Related]
2. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Talwar A; Estes E; Aparasu R; Reddy DS
Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
[TBL] [Abstract][Full Text] [Related]
5. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS
Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
[TBL] [Abstract][Full Text] [Related]
7. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Silvinato A; Floriano I; Bernardo WM
Rev Assoc Med Bras (1992); 2022; 68(10):1345-1357. PubMed ID: 36417631
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis.
Tong J; Ji T; Liu T; Liu J; Chen Y; Li Z; Lu N; Li Q
Epilepsy Behav; 2024 Mar; 152():109653. PubMed ID: 38277848
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
[TBL] [Abstract][Full Text] [Related]
10. Use of cannabidiol in the treatment of epilepsy.
Mazurkiewicz-Bełdzińska M; Zawadzka M
Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex.
Espinosa-Jovel C; Riveros S; Bolaños-Almeida C; Salazar MR; Inga LC; Guío L
Seizure; 2023 Nov; 112():72-76. PubMed ID: 37769547
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol in the Treatment of Epilepsy.
von Wrede R; Helmstaedter C; Surges R
Clin Drug Investig; 2021 Mar; 41(3):211-220. PubMed ID: 33559102
[TBL] [Abstract][Full Text] [Related]
15. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
[TBL] [Abstract][Full Text] [Related]
16. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
Franco V; Perucca E
Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
Golub V; Reddy DS
Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
[TBL] [Abstract][Full Text] [Related]
19. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH
Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197
[TBL] [Abstract][Full Text] [Related]
20. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
